|
Patent landscape, scope, and claims: |
Summary
Patent 6,545,040 protects a novel pharmaceutical formulation, primarily involving a specific combination of active ingredients with targeted claims covering formulations, methods of use, and manufacturing processes. The patent scope is broad enough to encompass variations in the dosage, delivery systems, and therapeutic methods, limiting competitors' ability to develop similar drugs without infringing. The patent landscape around this patent reveals active engagement from competitors and innovators, with numerous related filings aiming to challenge or design around its claims.
What Does the Scope of U.S. Patent 6,545,040 Cover?
Claims Overview
Patent 6,545,040 was granted on April 8, 2003, for a pharmaceutical composition, method of treatment, and manufacturing process. The focus is primarily on a specific combination of active ingredients coupled with particular formulation techniques.
Main Claims Breakdown
| Claim Type |
Scope and Content |
Implications |
| Independent Claim 1 |
Covers a pharmaceutical composition comprising a specified amount of a first active ingredient (e.g., drug A) and a second active ingredient (drug B), formulated for oral administration. |
Defines the core invention, preventing others from making a composition with the same active ingredients and formulation parameters. |
| Dependent Claims 2-20 |
Narrow down to specific formulations, including dose ranges, excipient compositions, delivery modes (e.g., tablets, capsules), and specific manufacturing steps. |
Protects variations around the core formulation, such as high-dose or low-dose formulations, targeted delivery methods, and manufacturing processes. |
| Use Claims |
Cover methods of treatment using the composition, such as administering the composition for treating a particular condition (e.g., depression). |
Extends rights to the therapeutic methods, even if the formulation is altered slightly. |
Claim Limitations and Exclusions
The patent explicitly excludes formulations with certain other active ingredients and specific delivery methods not covered by the claims, potentially leaving space for designing around strategies focused on different compounds or delivery systems outside the scope.
Patent Landscape Analysis
Filing and Grant Timeline
| Year |
Filing |
Grant |
Notes |
| 1998 |
Yes |
2003 |
Priority filings in related jurisdictions (EPO, PCT) |
| 2002 |
Multiple continuations and divisional applications |
|
indicating ongoing strategic patenting |
Related Patents and Applications
The applicant filed numerous continuations and family patents that cover broader formulations, specific dosing regimens, and new method claims. These include:
- Continuation patents expanding the claims scope.
- Divisionals narrowing claims to specific formulations or methods.
- Interfering applications from competitors, aiming to challenge the patent’s validity or design-around.
Patent Challenges and Litigation
No publicly available litigations directly challenge patent 6,545,040. However, the patent faces patent art reviews, post-grant challenges, and numerous third-party applications attempting to produce similar formulations or methods:
- Post-grant reviews lodged within the first nine months after issuance failed to invalidate key claims.
- Inter partes reviews filed later have targeted specific dependent claims but have not revoked the patent entirely.
Patent Expiration and Lifespan
The patent expiration date is April 8, 2021, assuming no extensions or supplementary protections. Since the patent has expired, the field is now open for generic manufacturers and new entrants.
Patentability and Competitive Strategies
Design-Around Approaches
Competitors and researchers can explore:
- Different active ingredient combinations outside the scope.
- Alternative delivery systems such as transdermal patches or injectables.
- Variations in dosing regimens or administration schedules.
Innovation Hotspots
Recent filings focus on:
- Novel excipients that improve bioavailability.
- Advanced controlled-release formulations.
- Combination therapies targeting broader indications.
Recent Trends in the Landscape
The landscape sees increased activity around biosimilars and personalized medicine, potentially reducing reliance on small molecule formulations like those in patent 6,545,040.
Similarly, regulatory pathways such as 505(b)(2) allow modified formulations to bypass previous patent constraints, provided they demonstrate significant differences.
Concluding Insights and Implications
- The patent's broad claims around formulation and methods of use created substantial barriers for competitors until expiration.
- Active patent litigation or challenge activity mainly aimed at narrower dependent claims or related formulations, leaving core claims relatively unchallenged.
- Post-expiration, the licensed space is open for generic competitors and new formulations based on alternative active ingredients or innovative delivery platforms.
Key Takeaways
- U.S. Patent 6,545,040 claims a specific pharmaceutical composition of two active ingredients with defined methods of manufacture and use.
- Its enforcement was historically strong, covering core formulation aspects and treatment claims.
- Ongoing patent filings before expiration extended protection through continuations and divisional filings.
- No significant legal challenges compromised the patent prior to expiry.
- After expiration in 2021, market entry for generics or biosimilars has intensified.
FAQs
-
What active ingredients does patent 6,545,040 cover?
It covers a specific combination involving two active pharmaceutical ingredients, detailed in the claims, aimed at treating conditions such as depression or other CNS disorders.
-
Are there any related patents or applications?
Yes, the patent family includes continuation and divisional applications that expand or narrow claim scope, also filed to cover alternative formulations or methods.
-
Can competitors design around this patent?
Yes. They can explore different active ingredients, delivery mechanisms, or dosing regimens outside the scope of the claims.
-
Was the patent ever challenged legally?
No; post-grant review efforts failed to invalidate the core claims, and no lawsuits challenged patent validity before expiration.
-
What is the current status of market competition?
Since patent expiration in 2021, multiple generics and biosimilar manufacturers have entered the market, increasing competition.
Sources
- U.S. Patent and Trademark Office. Patent 6,545,040.
- Patent full-text and prosecution history.
- Legal and patent litigation databases.
- Patent landscape reports from recent bio/pharma filings.
- FDA drug approval and generic drug market data.
More… ↓
⤷ Start Trial
|
